| Literature DB >> 10479159 |
D S Walsh1, S Looareesuwan, P Wilairatana, D G Heppner, D B Tang, T G Brewer, W Chokejindachai, P Viriyavejakul, D E Kyle, W K Milhous, B G Schuster, J Horton, D J Braitman, R P Brueckner.
Abstract
WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n=15) received 300 mg daily for 7 days; group B (n=11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n=9), 1 dose of 500 mg. A fourth group (D; n=9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n=23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10479159 DOI： 10.1086/315034
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226